Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Cash from Financing Activities (2016 - 2025)

Ligand Pharmaceuticals' Cash from Financing Activities history spans 16 years, with the latest figure at $8.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 59.14% year-over-year to $8.3 million; the TTM value through Dec 2025 reached $428.2 million, up 340.83%, while the annual FY2025 figure was $428.2 million, 340.83% up from the prior year.
  • Cash from Financing Activities for Q4 2025 was $8.3 million at Ligand Pharmaceuticals, down from $409.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $409.6 million in Q3 2025 and bottomed at -$170.4 million in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $1.4 million (2021), against an average of $2.6 million.
  • The largest annual shift saw Cash from Financing Activities plummeted 998000.0% in 2021 before it surged 1671.87% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $4.2 million in 2021, then crashed by 227.23% to -$5.3 million in 2022, then soared by 200.32% to $5.3 million in 2023, then surged by 283.59% to $20.4 million in 2024, then crashed by 59.14% to $8.3 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Cash from Financing Activities are $8.3 million (Q4 2025), $409.6 million (Q3 2025), and $15.0 million (Q2 2025).